A Three-Gene Signature for Predicting the Prognosis of Patients Treated with Transarterial Chemoembolization (TACE) and Identification of PD-184352 as a Potential Drug to Reverse Nonresponse to TACE

<div>Efficacy of the prognostic signature as verified by drug sensitivity test. (a) The relative mRNA expression of EPO, HMOX1, and SERPINE1 in Hep G2 and Hep 3B. (b, c) IC50 of lobaplatin on Hep 3B was detected in normoxic and hypoxic environments. (d, e) IC50 of lobaplatin on Hep 3B was detected in normoxic and hypoxic environments.</div>

Journal of Oncology

fig7

Figure 7

Figure 7: A Three-Gene Signature for Predicting the Prognosis of Patients Treated with Transarterial Chemoembolization (TACE) and Identification of PD-184352 as a Potential Drug to Reverse Nonresponse to TACE 

Figure 7 | A Three-Gene Signature for Predicting the Prognosis of Patients Treated with Transarterial Chemoembolization (TACE) and Identification of PD-184352 as a Potential Drug to Reverse Nonresponse to TACE 